A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JMT206 Injection in Healthy Subjects
Latest Information Update: 02 Mar 2026
At a glance
- Drugs JMT 206 (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors Shanghai JMT-BIO Technology
Most Recent Events
- 02 Mar 2026 New trial record